Publications by authors named "Endre Stokke"
Article Synopsis
- Triple-negative breast cancer (TNBC) lacks effective therapies due to unresponsiveness to endocrine and anti-HER2 treatments, leading to reliance on chemotherapy and highlighting the need for biomarkers that can predict treatment responses.
- A study utilizing metabolomics to evaluate the effects of the mTOR inhibitor everolimus on TNBC patient-derived xenografts revealed a 67% accuracy in distinguishing treated from untreated tumors, indicating reductions in glycolytic lactate and glutaminolysis.
- Although metabolic differences among xenograft models complicated predictions of treatment response, noticeable metabolic changes in responding tumors suggest potential for using metabolic information in conjunction with mutation status, like p53, to enhance understanding of TNBC treatment outcomes.
